The AMI Essentials course teaches complex facial anatomy to aesthetic physicians who offer non-surgical facial aesthetic procedures
Dubai, United Arab Emirates: Allergan, a global biopharmaceutical company and leader in medical aesthetics, recently announced that it held a Allergan Medical Institute® (AMI) Essentials Applied Anatomy course in Dubai, United Arab Emirates. The course aimed to provide world-class training for aesthetic physicians and doctors in the region, in order to enhance patient safety and optimise outcomes in medical aesthetics.
A detailed knowledge of facial anatomy, in particular the facial vascular framework, is essential to for doctors and aesthetic physicians to carry out safe and effective nonsurgical aesthetic procedures. Moreover, an in-depth understanding of facial injection techniques is vital to avoid adverse complications.
The aesthetics market plays a key role in the UAE healthcare sector, as Dubai holds one of the highest ratios of plastic surgeons per capita in the world.[1] Globally, the medical aesthetics industry is expected to reach $73 billion by the year 2022, with Dubai being one of the most promising cities for the sector.[2]
“The AMI Essentials course in Dubai provides the infrastructure to enable doctors and aesthetic physicians to further enhance their understanding of facial anatomy to deliver better patient outcomes” said Ramsey Morad, Allergan’s Vice President for India, Middle East and Africa. “The international curriculum has been developed in consultation with world renowned aesthetic physicians and plastic surgeons” he continued.
Narendra Kumar, Director of the Allergan Medical Institute noted “Allergan AMI courses are founded on three key pillars; professional development, partnership and continued innovation.” The international courses aim to provide world-class medical education for doctors in order to accelerate scientific knowledge and technical skills in the field of medical aesthetics. Being part of the AMI expert faculty means doctors gain inside knowledge and hands-on experience to ensure they are at the forefront of the field of aesthetics.
The intensive two-day course provides a comprehensive approach to injecting patients and allows participants to practice on cadavers as well as live models. Cadaver dissection is used to familiarise participants with underlying anatomical facial structures with an emphasis on critical neurovasculature, fat compartments and muscles of the upper, mid and lower face. Dissecting cadavers also allows familiarisation with common structural variations to ensure a full knowledge of exposed structures that could potentially be damaged during invasive treatment.
Participants also witness live demonstration of safer injection techniques on male and female models across the full spectrum of young and mature skin using a variety of injectable treatments. This allows the doctors to learn how to tailor treatment to the patient’s individual attributes and inject to ensure a natural-looking result.
Dr. Khalid Al Awadi, Consultant Plastic and Hand Surgeon at Acacia Medical Centre also noted, “learning the anatomy of the face inside out will allow aesthetic doctors to holistically plan treatment to deliver the best possible results that are consistently natural-looking. As doctors, we are encouraged to question the strategy behind treatment and visualize the outcome that can be achieved by injecting specific areas.”
“Allergan is strongly committed to bring in best in class evidence-based courses to every physician in the region to optimise patient outcomes. We pursue this goal through ongoing training with our products, hand-on workshops led by experts to stimulate scientific exchange, and lastly, sharing of best practices to support medical education and ongoing studies. These activities all support our underlying commitment to promote excellence in clinical practice” added Kumar.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan’s success is powered by our global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan’s current expectations depending upon a number of factors affecting Allergan’s business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan’s products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
© Press Release 2019Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
